Vescor, advised by its scientific founders White and Kimmelman, whose research has shown inhibition
of autophagy can dramatically impact tumor growth in pre‐clinical models, will develop small molecule
inhibitors of a number of protein targets at critical nodes of the autophagy cascade, perform investigational new drug (IND) enabling studies, and move these into clinical development. MD Anderson’s Institute for Applied Cancer Science (IACS) in combination with Deerfield will provide drug discovery and development expertise, together with translational research focused at advancing autophagy therapeutics into trials in melanoma, lung and pancreatic cancers.
